ProQR Total Assets from 2010 to 2025

PRQR Stock

USD 1.65 0.00 0.00%

ProQR Therapeutics Total Assets yearly trend continues to be relatively stable with very little volatility. Total Assets are likely to drop to about 114.4 M. Total Assets is the total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets. View All Fundamentals

Total Assets

First Reported

2012-12-31

Previous Quarter

106.9 M

Current Value

168 M

Quarterly Volatility

49 M

Yuan Drop

Covid

Check ProQR Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among ProQR Therapeutics' main balance sheet or income statement drivers, such as Interest Expense of 1.4 M, Total Revenue of 19.9 M or Research Development of 31.2 M, as well as many indicators such as Price To Sales Ratio of 10.5, Dividend Yield of 0.0 or PTB Ratio of 2.48. ProQR financial statements analysis is a perfect complement when working with ProQR Therapeutics Valuation or Volatility modules.

Check out the analysis of ProQR Therapeutics Correlation against competitors.

Latest ProQR Therapeutics' Total Assets Growth Pattern

Below is the plot of the Total Assets of ProQR Therapeutics BV over the last few years. Total assets refers to the total amount of ProQR Therapeutics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in ProQR Therapeutics books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. It is the total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets. ProQR Therapeutics' Total Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in ProQR Therapeutics' overall financial position and show how it may be relating to other accounts over time.

View

Last Reported 167.96 M

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Total Assets

Timeline

ProQR Total Assets Regression Statistics

	Arithmetic Mean	91,697,673
	Geometric Mean	31,302,813
	Coefficient Of Variation	71.90
	Mean Deviation	53,252,755
	Median	110,231,000
	Standard Deviation	65,930,388
	Sample Variance	4346.8T
	Range	209.2M
	R-Value	0.83
	Mean Square Error	1485.7T
	R-Squared	0.68
	Significance	0.000083
	Slope	11,427,893
	Total Sum of Squares	65202.2T

ProQR Total Assets History

	2025	114.4 M
	2024	168 M
	2023	137.9 M
	2022	171.3 M
	2021	209.6 M
	2020	98.7 M
	2019	117.5 M

Other Fundumenentals of ProQR Therapeutics

Intangibles To Total Assets

ProQR Therapeutics Total Assets component correlations

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Long Term Debt	Net Receivables	Total Liab	Total Current Assets	Common Stock	Net Tangible Assets	Current Deferred Revenue	Short Long Term Debt	Short Term Debt	Property Plant Equipment	Long Term Debt Total	Capital Surpluse	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		0.85	-0.89	-0.8	0.13	0.64	0.35	0.83	1.0	0.82	0.82	0.5	0.03	0.36	0.73	0.66	0.62	0.69	0.84	0.72
Total Stockholder Equity	0.85		-0.9	-0.46	0.13	0.59	0.08	0.4	0.88	0.56	0.98	0.21	0.21	0.05	0.38	0.58	0.57	0.64	0.59	0.35
Net Debt	-0.89	-0.9		0.69	-0.17	-0.5	-0.06	-0.58	-0.91	-0.79	-0.9	-0.59	-0.12	-0.26	-0.58	-0.61	-0.59	-0.63	-0.69	-0.62
Retained Earnings	-0.8	-0.46	0.69		0.06	-0.42	-0.36	-0.89	-0.77	-0.98	-0.42	-0.81	0.22	-0.62	-0.92	-0.65	-0.61	-0.57	-0.83	-0.91
Accounts Payable	0.13	0.13	-0.17	0.06		-0.18	-0.03	0.09	0.14	-0.06	0.3	0.04	0.26	-0.49	-0.1	-0.17	-0.18	-0.41	-0.25	-0.06
Long Term Debt	0.64	0.59	-0.5	-0.42	-0.18		-0.09	0.47	0.63	0.41	0.53	0.06	-0.08	0.39	0.49	0.43	0.41	0.85	0.69	0.26
Net Receivables	0.35	0.08	-0.06	-0.36	-0.03	-0.09		0.52	0.33	0.31	0.05	0.06	-0.06	0.18	0.31	0.18	0.16	0.04	0.4	0.37
Total Liab	0.83	0.4	-0.58	-0.89	0.09	0.47	0.52		0.79	0.82	0.38	0.64	-0.17	0.57	0.86	0.53	0.48	0.51	0.83	0.88
Total Current Assets	1.0	0.88	-0.91	-0.77	0.14	0.63	0.33	0.79		0.8	0.85	0.48	0.06	0.32	0.69	0.66	0.62	0.69	0.83	0.69
Common Stock	0.82	0.56	-0.79	-0.98	-0.06	0.41	0.31	0.82	0.8		0.53	0.83	-0.15	0.61	0.89	0.64	0.61	0.59	0.81	0.9
Net Tangible Assets	0.82	0.98	-0.9	-0.42	0.3	0.53	0.05	0.38	0.85	0.53		0.23	0.27	-0.04	0.35	0.5	0.49	0.53	0.51	0.3
Current Deferred Revenue	0.5	0.21	-0.59	-0.81	0.04	0.06	0.06	0.64	0.48	0.83	0.23		-0.15	0.62	0.75	0.34	0.31	0.25	0.51	0.86
Short Long Term Debt	0.03	0.21	-0.12	0.22	0.26	-0.08	-0.06	-0.17	0.06	-0.15	0.27	-0.15		-0.3	-0.18	-0.12	-0.1	-0.19	-0.23	-0.19
Short Term Debt	0.36	0.05	-0.26	-0.62	-0.49	0.39	0.18	0.57	0.32	0.61	-0.04	0.62	-0.3		0.7	0.11	0.08	0.53	0.63	0.72
Property Plant Equipment	0.73	0.38	-0.58	-0.92	-0.1	0.49	0.31	0.86	0.69	0.89	0.35	0.75	-0.18	0.7		0.48	0.44	0.51	0.73	0.86
Long Term Debt Total	0.66	0.58	-0.61	-0.65	-0.17	0.43	0.18	0.53	0.66	0.64	0.5	0.34	-0.12	0.11	0.48		1.0	0.65	0.7	0.44
Capital Surpluse	0.62	0.57	-0.59	-0.61	-0.18	0.41	0.16	0.48	0.62	0.61	0.49	0.31	-0.1	0.08	0.44	1.0		0.63	0.66	0.4
Net Invested Capital	0.69	0.64	-0.63	-0.57	-0.41	0.85	0.04	0.51	0.69	0.59	0.53	0.25	-0.19	0.53	0.51	0.65	0.63		0.88	0.46
Net Working Capital	0.84	0.59	-0.69	-0.83	-0.25	0.69	0.4	0.83	0.83	0.81	0.51	0.51	-0.23	0.63	0.73	0.7	0.66	0.88		0.75
Capital Stock	0.72	0.35	-0.62	-0.91	-0.06	0.26	0.37	0.88	0.69	0.9	0.3	0.86	-0.19	0.72	0.86	0.44	0.4	0.46	0.75

Click cells to compare fundamentals

About ProQR Therapeutics Financial Statements

ProQR Therapeutics shareholders use historical fundamental indicators, such as Total Assets, to determine how well the company is positioned to perform in the future. Although ProQR Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in ProQR Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on ProQR Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.

		Last Reported	Projected for Next Year
	Total Assets	168 M	114.4 M

Pair Trading with ProQR Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if ProQR Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ProQR Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving together with ProQR Stock

0.81	CDIOW	Cardio Diagnostics	Pair Corr
0.72	ELVN	Enliven Therapeutics	Pair Corr

Moving against ProQR Stock

0.57	GE	GE Aerospace	Pair Corr
0.55	WM	Waste Management	Pair Corr
0.5	LUCD	Lucid Diagnostics	Pair Corr
0.47	PLX	Protalix Biotherapeutics	Pair Corr

The ability to find closely correlated positions to ProQR Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace ProQR Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back ProQR Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling ProQR Therapeutics BV to buy it.

The correlation of ProQR Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as ProQR Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if ProQR Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for ProQR Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

Additional Tools for ProQR Stock Analysis

When running ProQR Therapeutics' price analysis, check to measure ProQR Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ProQR Therapeutics is operating at the current time. Most of ProQR Therapeutics' value examination focuses on studying past and present price action to predict the probability of ProQR Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ProQR Therapeutics' price. Additionally, you may evaluate how the addition of ProQR Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC